P18

General Information


DRACP ID  DRACP00229

Peptide Name   P18

Sequence  KWKLFKKIPKFLHLAKKF

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
M14 Amelanotic melanoma Carcinoma 92.2 ± 1.02% cell viability at 10 µM, 71.1 ± 2.84% cell viability at 20 µM, 50 ± 3.09% cell viability at 40 µM, 31.5 ± 1.49% cell viability at 60 µM, 13.8 ± 1.44% cell viability at 80 µM MTT assay Not available 1
A-375 Amelanotic melanoma Carcinoma 86 ± 0.57% cell viability at 10 µM, 63.8 ± 0.8% cell viability at 20 µM, 47.5 ± 1.66% cell viability at 40 µM, 26.9 ± 0.5% cell viability at 60 µM, 6.5 ± 1.07% cell viability at 80 µM MTT assay Not available 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  99 ± 1.6% cell viability at 10 µM, 98 ± 1.6% cell viability at 20 µM, 75.2 ± 5.6% cell viability at 40 µM, 70.8 ± 3.6% cell viability at 60 µM, 47.7 ± 3.1% cell viability at 80 µM

Target  Not available

Affinity  Not available

Mechanism  Amphiphilic α-helical structure of P18 peptide, coupled with changes in ion channels and an increase in plasma membrane permeability that eventually leads to melanoma cell death

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00229

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C118H186N28O19

Absent amino acids  CDEGMNQRSTVY

Common amino acids  K

Mass  260436

Pl  11.58

Basic residues  8

Acidic residues  0

Hydrophobic residues  9

Net charge  8

Boman Index  -1075

Hydrophobicity  -38.33

Aliphatic Index  92.22

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  323.53

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 19957017

Title  Anti-melanoma activity of hybrid peptide P18 and its mechanism of action

Doi 10.1007/s10529-009-0175-2

Year  2010

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.